NEW YORK (GenomeWeb) – Enzo Biochem reported today that its fiscal third quarter revenues climbed 10 percent over last year on a strong performance for its clinical lab and life science divisions.

For the three-month period ended April 30, the company reported total revenues of $26.4 million compared to $24 million in the same period a year earlier. Clinical lab services revenues grew 16 percent to $18.2 million from $15.7 million, while life sciences revenues edged up to $8 million from $7.9 million. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.